Joan Seoane Vall d’Hebron Institute of Oncology (VHIO)

Vall d’Hebron University Hospital Barcelona

Vall d'Hebron

Hospital General

Everything you always wanted to know about creating a company

(but were afraid to ask)

• The Idea

• The Company

• The Death Valley

• The TEAM, founders

• The TEAM, investors and advisors

The Idea, The Science

Once upon a time…2008 A research group…publish or perish

LIF in Cancer

5

LIF

LIF

LIF

Glioma-initiating cells

LIF

Let’s patent…”vols dir?” (is it really necessary…?)

Patent 1, the target Patent 2, the product

• Cytokine of the IL6 family

• Crucial for embryonic stem cells

• Crucial for embryo implantation

• Induces neural stem cell self-renewal

• Induces glial differentiation

• Role in immune system

Leukemia Inhibitory Factor (LIF)

LIF

Stat3

Stat3

JAK

LIFR GP130

The compound. A fully humanized antibody

MSC-1

PBS

Anti-

LIF D

30

10

20

30 * p=0.0175

0 10 20 300

5

10

15

Control

MSC-1

Days after

cell inoculation

MSC-1 (15mg/kg)

Control MSC-1

Tu

mo

r V

olu

me

(Flu

x [

p/s

] fo

ld i

ncre

ase)

MSC-1 Promotes Tumor Regression

Radia

nce

(p/s

ec/c

m2/s

r)

MSC-1: A personalized medicine approach Developing a CDx to stratify patients

High LIF

• LIF KO mice are viable but infertile (no implantation of blastocysts)1

• Women with mutations in LIF gene are healthy although infertile

1 Stewart et al. Nature 1992; 359: 76-9; Escary et al. Nature 1993; 363: 361-4; Chen et al. Endocrinology

2000; 141: 4365-72.

Toxicity

It looks promising… Will it work in patients?

Spin-off company

It’s the TEAM, stupid

The founders

Let’s talk about her

Biomedicals

Foundation

Josep Baselga, MD, PhD

Chair SAB, co-founder

Joan Seoane, PhD

Chairman, co-founder

Judit Anido, PhD, MBA

CEO, co-founder

The Institutions

The Death Valley

Financial support

Winner “Best

entrepreneurial project” Winner

Recognition

The TEAM, The TEAM, The TEAM

Frank McCormick, PhD, FRS Co-Chair of the SAB

David A. Wood Distinguished

Professor of Tumor Biology and

Cancer Research at the UCSF

School of Medicine.

Previously was the Founder and

CSO at Onyx Pharmaceuticals.

He also served as VP of

Research at Chiron Corporation

and Cetus Corporation.

Mosaic’s Team

Scientific Advisors

Mosaic’s Team

Business Angels

Mosaic’s Team

Investors

Mosaic’s Team

Investors

Guido Magni, MD, PhD

Member of the BoD

Gianni Gromo, MD, PhD

Member of the BoD

Partner at Versant Ventures.

Previously served as a Senior

Executive at Roche including

Research Head of Global

Cardiovascular and Metabolic

Research, Head of Discovery

Research (Basel site), Global Head

of the Metabolic and Vascular

Disease Business Unit, and Head of

the Roche China R&D center.

Partner at Versant Ventures.

Previously served as Managing

Director of EuroVentures, a

Versant incubator and Global

Head of the Medical Science

Department of Roche

Pharmaceuticals. Among others

oversaw the development and

the registration Mabthera,

Xeloda, Herceptin and Tarceva.

Mosaic’s Team

Consultants Kent Iverson - Manufacturing - San Francisco, California, US 18 years experience in manufacturing including Genentech (Protropin™, Activase™); Immunex (9 years, Leukine™, Enbrel™);

Coulter (Bexxar-radiolabeled antibody for cancer treatment) and Corixa (VP of Process Development). Current advisor at Lonza.

Claire Barton - Clinical Development - London, UK Medical oncologist/pharmaceutical physician specializing in the clinical development of products for oncology indications.

Former positions at Roche Products Ltd (Clinical Science Leader for Herceptin); Eli Lilly and Co. Ltd (European Clinical

Development Physician) and Glaxo Wellcome.

Karin Jorga - Clinical Development - Basel, Switzerland More than 20 years experience at Roche in transitioning pre-clinical lead molecules to Clinical Proof-of-Concept and advancing

novel biomarkers to drive Personalized Healthcare of small and large molecules across all therapeutic areas.

Jennifer Sims - Pre-clinical and Tox Development - Basel, Switzerland European Registered Toxicologist with 15 years experience in preclinical drug development including non-clinical

pharmacology, translational PK-PD and safety assessment for new medicinal products. Former positions at Novartis (Head of

Translational Sciences & Safety) and Astra Zeneca/MedImmune (Global Head Biopharma Safety Assessment)

NDA REG - Regulatory Drug Development - Zurich, Switzerland Paul Chamberlain: 35 years of experience. Specialized on the design of IND enabling packages for antibodies for

oncology.

Klass Zuideveld - Companion Diagnostic Development - Basel, Switzerland 14 years experience in the development of companion diagnostics. Former positions at Hoffmann-La Roche Ltd Pharma

(Product Optimization Leader); F. Hoffmann-La Roche Ltd. Diagnostics Providing strategic support to the Diagnostics COO and

at Roche NimbleGen as a Director of Personalized Healthcare among others.

Len Presta- Antibody Engineering- Palo Alto, California, US 30 years of experience in protein/antibody engineering. At Genentech: responsible for the protein engineering that led to

marketed therapeutic monoclonal antibodies Herceptin, Raptiva, Xolair, Avastin, Lucentis, Perjeta and therapeutic protein

Tenecteplase. At Merck (formerly Schering-Plough, DNAX): responsible for protein and antibody engineering of internal

therapeutic antibodies in the pipeline.

The Company

Work, Work, Work

First the patients!

Stupp et al. New Engl. J. Med. 2005

VALUE CREATION

Stage: Pre-clinical

Stage: Phase I/II Clinical trial

Business strategy

Stage: Compound development Regulatory toxicology

Sky is the limit, enjoy the journey and go for your dreams